|
Variable
|
T1
|
T2
|
T3
|
Time*group
|
Time*group*gender
|
|---|
|
Urea Nitrogen (mg/dL)
|
|
PLA
|
16 ± 4
|
15 ± 4
|
16 ± 5
|
Time p = 0.89
|
G*T*Ge p = 0.39
|
|
LD
|
14 ± 3
|
14 ± 3
|
15 ± 3
|
G*T p = 0.34
|
|
HD
|
15 ± 4
|
13 ± 4
|
14 ± 3
|
|
Creatinine (mg/dL)
|
|
PLA
|
1.18 ± 0.2
|
0.96 ± 0.2
|
0.97 ± 0.2
|
Time p = 0.33
|
G*T*Ge
p
= 0.046
|
|
LD
|
0.97 ± 0.1
|
1.02 ± 0.2
|
1.03 ± 0.2
‡
|
G*T p = 0.06
|
|
HD
|
0.99 ± 0.2
|
1.01 ± 0.2
|
1.05 ± 0.2
|
|
Sodium (mmoL)
|
|
PLA
|
140.65 ± 3
|
139.85 ± 2
|
140.95 ± 2
|
Time
p
= 0.007
|
G*T*Ge p = 0.84
|
|
LD
|
141.22 ± 2
|
140.17 ± 2
|
140.95 ± 3
|
G*T p = 0.67
|
|
HD
|
141.19 ± 3
|
139.95 ± 2
†
|
140.24 ± 2
|
|
Potassium (mmoL)
|
|
PLA
|
4.9 ± 0.4
|
4.7 ± 0.6
|
4.9 ± 0.5
|
Time p = 0.22
|
G*T*Ge p = 0.99
|
|
LD
|
5.0 ± 0.6
|
4.8 ± 0.4
|
4.9 ± 0.5
|
G*T p = 0.97
|
|
HD
|
4.9 ± 0.4
|
4.8 ± 0.4
|
4.9 ± 0.4
|
|
Chloride (mmoL)
|
|
PLA
|
105.60 ± 2
|
104.45 ± 2
†
|
105.00 ± 2
|
Time
p
= 0.006
|
G*T*Ge p = 0.60
|
|
LD
|
105.89 ± 2
|
105.33 ± 2
|
104.84 ± 2
|
G*T p = 0.78
|
|
HD
|
105.24 ± 2
|
104.33 ± 2
†
|
104.57 ± 2
|
|
Calcium (mg/dL)
|
|
PLA
|
9.7 ± 0.5
|
9.5 ± 0.4
|
9.6 ± 0.4
|
Time p = 0.37
|
G*T*Ge p = 0.74
|
|
LD
|
9.6 ± 0.3
|
9.6 ± 0.4
|
9.6 ± 0.3
|
G*T p = 0.20
|
|
HD
|
9.8 ± 0.3
|
9.7 ± 0.4
|
9.7 ± 0.3
|
|
Carbon Dioxide (mmoL)
|
|
PLA
|
24 ± 2
|
25 ± 2
|
24 ± 2
|
Time p = 0.65
|
G*T*Ge p = 0.95
|
|
LD
|
26 ± 2
|
26 ± 2
|
25 ± 2
|
G*T p = 0.85
|
|
HD
|
25 ± 2
|
25 ± 2
|
25 ± 2
|
- Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
- Symbols: ‡, increase from corresponding T1 value within the male TC-LD group (p < 0.05); †, different from corresponding T1 value (p < 0.05). Items in bold indicate a significant effect (p < 0.05) was observed
